Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
751 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01724021 | A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a | completed | Phase 3 | 743 | Hoffmann-La RocheINDUSTRY | 32 | Jan 23, 2018 | clinicaltrials |
| NCT03106662 | Mesenchymal Stem Cell Infusion in Haploidentical Hematopoietic Stem Cell Transplantation in Patients With Hematological Malignancies | completed | Phase 3 | 6 | Ankara UniversityOTHER | 1 | Jan 10, 2018 |
| clinicaltrials |
| NCT01307397 | A Study of Vemurafenib in Participants With Metastatic Melanoma | completed | Phase 3 | 3,219 | Hoffmann-La RocheINDUSTRY | 44 | Dec 18, 2017 | clinicaltrials |
| NCT01722487 | Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL | completed | Phase 3 | 269 | Pharmacyclics LLC.INDUSTRY | 16 | Nov 30, 2017 | clinicaltrials |
| NCT01649856 | A Study of Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell Lymphoma | completed | Phase 3 | 572 | Hoffmann-La RocheINDUSTRY | 27 | Oct 11, 2017 | clinicaltrials |
| NCT02149108 | Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1) | completed | Phase 3 | 768 | Boehringer IngelheimINDUSTRY | 25 | Jul 21, 2017 | clinicaltrials |
| NCT00790036 | Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy(PILLAR2) | completed | Phase 3 | 742 | Novartis PharmaceuticalsINDUSTRY | 34 | Jul 12, 2017 | clinicaltrials |
| NCT01641939 | A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer | terminated | Phase 2 / Phase 3 | 415 | Hoffmann-La RocheINDUSTRY | 28 | May 12, 2017 | clinicaltrials |
| NCT00863655 | Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole(BOLERO-2) | completed | Phase 3 | 724 | Novartis PharmaceuticalsINDUSTRY | 24 | May 2, 2017 | clinicaltrials |
| NCT01308580 | Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer(PROSELICA) | completed | Phase 3 | 1,200 | SanofiINDUSTRY | 22 | Apr 17, 2017 | clinicaltrials |
| NCT00384176 | First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX(HORIZON III) | completed | Phase 2 / Phase 3 | 1,814 | AstraZenecaINDUSTRY | 28 | Apr 14, 2017 | clinicaltrials |
| NCT01007942 | Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer(BOLERO-3) | completed | Phase 3 | 569 | Novartis PharmaceuticalsINDUSTRY | 21 | Apr 5, 2017 | clinicaltrials |
| NCT01910987 | Study to Evaluate Optimized Retreatment and Prolonged Therapy With Bortezomib(OPTIMRETREAT) | completed | Phase 3 | 80 | Janssen-Cilag International NVINDUSTRY | 11 | Feb 17, 2017 | clinicaltrials |
| NCT00481247 | A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia(DASISION) | completed | Phase 3 | 547 | Bristol-Myers SquibbINDUSTRY | 27 | Feb 15, 2017 | clinicaltrials |
| NCT00806819 | Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC | completed | Phase 3 | 718 | Boehringer IngelheimINDUSTRY | 32 | Feb 2, 2017 | clinicaltrials |
| NCT00154102 | Cetuximab Combined With Irinotecan in First-line Therapy for Metastatic Colorectal Cancer (CRYSTAL)(CRYSTAL) | completed | Phase 3 | 1,221 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 30 | Jan 30, 2017 | clinicaltrials |
| NCT00405756 | A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older. | completed | Phase 3 | 459 | Celgene CorporationINDUSTRY | 22 | Jan 11, 2017 | clinicaltrials |
| NCT01450696 | A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer(HELOISE) | terminated | Phase 3 | 296 | Hoffmann-La RocheINDUSTRY | 25 | Nov 28, 2016 | clinicaltrials |
| NCT00021255 | Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer | completed | Phase 3 | 3,222 | SanofiINDUSTRY | 42 | Nov 15, 2016 | clinicaltrials |
| NCT01662869 | A Study of Onartuzumab in Combination With mFOLFOX6 in Participants With Metastatic HER2-Negative and MET-Positive Gastroesophageal Cancer | completed | Phase 3 | 564 | Hoffmann-La RocheINDUSTRY | 24 | Nov 2, 2016 | clinicaltrials |
| NCT00858871 | First Line Hepato Cellular Carcinoma (HCC)(BRISK FL) | completed | Phase 3 | 1,714 | Bristol-Myers SquibbINDUSTRY | 26 | Oct 17, 2016 | clinicaltrials |
| NCT00069095 | A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer | completed | Phase 3 | 2,035 | Hoffmann-La RocheINDUSTRY | 33 | Oct 6, 2016 | clinicaltrials |
| NCT00312377 | ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer(ZODIAC) | completed | Phase 3 | 1,690 | Genzyme, a Sanofi CompanyINDUSTRY | 25 | Sep 30, 2016 | clinicaltrials |
| NCT00056407 | "REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk(REDUCE) | completed | Phase 3 | 8,231 | GlaxoSmithKlineINDUSTRY | 42 | Sep 23, 2016 | clinicaltrials |
| NCT00002523 | Radiation Therapy, Surgery, and Chemotherapy in Treating Patients With Rectal Cancer That Can Be Surgically Removed | completed | Phase 3 | 1,011 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 10 | Sep 2, 2016 | clinicaltrials |
| NCT01057810 | Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer | completed | Phase 3 | 837 | Bristol-Myers SquibbINDUSTRY | 24 | Aug 18, 2016 | clinicaltrials |
| NCT00519285 | Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer(VENICE) | completed | Phase 3 | 1,224 | SanofiINDUSTRY | 31 | Jul 22, 2016 | clinicaltrials |
| NCT00686959 | Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer(PROCLAIM) | completed | Phase 3 | 598 | Eli Lilly and CompanyINDUSTRY | 19 | Jun 28, 2016 | clinicaltrials |
| NCT00785785 | A Study of Nilotinib Versus Imatinib in GIST Patients(ENESTg1) | completed | Phase 3 | 644 | Novartis PharmaceuticalsINDUSTRY | 35 | Jun 16, 2016 | clinicaltrials |
| NCT01239732 | A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer | completed | Phase 3 | 1,021 | Hoffmann-La RocheINDUSTRY | 37 | Jun 10, 2016 | clinicaltrials |
| NCT00417209 | Larotaxel Compared To Continuous Administration of 5-FU in Advanced Pancreatic Cancer Patients Previously Treated With A Gemcitabine-Containing Regimen(PAPRIKA) | completed | Phase 3 | 408 | SanofiINDUSTRY | 21 | Jun 3, 2016 | clinicaltrials |
| NCT00400478 | A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation in Patients With Aggressive B-cell Lymphoma: NHL-13 | completed | Phase 3 | 683 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 26 | May 26, 2016 | clinicaltrials |
| NCT00625664 | Larotaxel + Cisplatin Versus Gemcitabine + Cisplatin in First Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer(CILAB) | completed | Phase 3 | 337 | SanofiINDUSTRY | 19 | May 5, 2016 | clinicaltrials |
| NCT01151410 | An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age | completed | Phase 3 | 208 | Novartis PharmaceuticalsINDUSTRY | 7 | Mar 7, 2016 | clinicaltrials |
| NCT00961415 | AVAPERL1 Study: A Study of Avastin (Bevacizumab) With or Without Pemetrexed as Maintenance Therapy After Avastin in First Line in Patients With Non-Squamous Non-Small Cell Lung Cancer | completed | Phase 3 | 376 | Hoffmann-La RocheINDUSTRY | 12 | Feb 22, 2016 | clinicaltrials |
| NCT01697072 | First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma(RILOMET-1) | terminated | Phase 3 | 609 | AmgenINDUSTRY | 27 | Feb 9, 2016 | clinicaltrials |
| NCT01532453 | Prevention of UV-induced Carcinogenic Skin Alterations in Immunosuppressed Solid Organ Transplanted Patients | terminated | Phase 3 | 244 | Spirig Pharma Ltd.INDUSTRY | 9 | Jan 8, 2016 | clinicaltrials |
| NCT02598414 | The Role of Indocyanine Green (ICG) Fluorescence Imaging on Anastomotic Leak in Robotic Colorectal Surgery | unknown | Phase 2 / Phase 3 | 102 | Acibadem UniversityOTHER | 1 | Nov 24, 2015 | clinicaltrials |
| NCT01234311 | A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer | completed | Phase 3 | 1,245 | Active Biotech ABINDUSTRY | 37 | Oct 21, 2015 | clinicaltrials |
| NCT00391092 | A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer. | completed | Phase 3 | 424 | Hoffmann-La RocheINDUSTRY | 16 | Aug 28, 2015 | clinicaltrials |
| NCT01183858 | A Study of Tarceva (Erlotinib) to Compare Two Different Doses in in Currently Smoking Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (CURRENTS) | completed | Phase 3 | 315 | Hoffmann-La RocheINDUSTRY | 9 | Aug 19, 2015 | clinicaltrials |
| NCT01423500 | ALL-SCT BFM International- HSCT in Children and Adolescents With ALL(ALL-SCT-BFMi) | unknown | Phase 3 | 405 | St. Anna KinderkrebsforschungOTHER | 11 | Jun 26, 2015 | clinicaltrials |
| NCT01103323 | Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy | completed | Phase 3 | 760 | BayerINDUSTRY | 19 | Jun 24, 2015 | clinicaltrials |
| NCT00448591 | A Study of Avastin (Bevacizumab) Plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer. | completed | Phase 3 | 2,296 | Hoffmann-La RocheINDUSTRY | 36 | May 25, 2015 | clinicaltrials |
| NCT00075270 | Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer | completed | Phase 3 | 580 | GlaxoSmithKlineINDUSTRY | 25 | May 6, 2015 | clinicaltrials |
| NCT00254904 | Randomized Trial of Gemcitabine/Cisplatin + PF-3512676 vs Gemcitabine/Cisplatin Alone in Patients With Advanced NSCLC | terminated | Phase 3 | 839 | PfizerINDUSTRY | 24 | Mar 30, 2015 | clinicaltrials |
| NCT01450449 | Short Course vs. Standard Course Radiotherapy in Elderly and/or Frail Patients With Glioblastoma Multiforme | completed | Phase 3 | 115 | International Atomic Energy AgencyOTHER_GOV | 14 | Mar 24, 2015 | clinicaltrials |
| NCT00929240 | A Study of Avastin (Bevacizumab) + Xeloda (Capecitabine)as Maintenance Therapy in Patients With HER2-Negative Metastatic Breast Cancer | completed | Phase 3 | 287 | Hoffmann-La RocheINDUSTRY | 11 | Mar 3, 2015 | clinicaltrials |
| NCT00006249 | Interferon Alfa Following Surgery in Treating Patients With Stage III Melanoma | unknown | Phase 3 | 1,258 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 18 | Feb 10, 2015 | clinicaltrials |
| NCT00863746 | A 3rd/4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC).(MISSION) | completed | Phase 3 | 703 | BayerINDUSTRY | 34 | Jan 19, 2015 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials